Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463764 | 0.83 | MAPK14 (0.91) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL5759775 | 0.81 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL6599608 | 0.79 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4105858 | 0.77 | MAPK13 (0.60) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL5762007 | 0.76 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL5763554 | 0.74 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4102731 | 0.74 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL4102181 | 0.73 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL5762949 | 0.73 | MAPK13 (0.62) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL11469982 | 0.72 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005105814-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.